C12N 2750/14133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2750/14133 (Use of viral protein as therapeutic agent other than vaccine) appears on 52 US grants and 100 published applications in this corpus.
Search patents in C12N- Granted patents
- 52
- Published applications
- 100
- Assignees
- 56
- Inventors
- 134
- Latest grant
- 6 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 1 |
| 2013 | 0 | 3 |
| 2014 | 1 | 3 |
| 2015 | 2 | 3 |
| 2016 | 2 | 6 |
| 2017 | 3 | 6 |
| 2018 | 3 | 6 |
| 2019 | 5 | 16 |
| 2020 | 4 | 9 |
| 2021 | 7 | 12 |
| 2022 | 1 | 8 |
| 2023 | 7 | 9 |
| 2024 | 9 | 8 |
| 2025 | 6 | 5 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Gene therapies for lysosomal disorders6 Jan 2026US 12,516,298 B2Prevail Therapeutics, Inc.
- Circuit board16 Dec 2025US 12,501,545 B2LG Innotek Co., Ltd.
- Modulation of SPTLC1 via recombinant adeno-associated vectors19 Aug 2025US 12,391,947 B2University of Massachusetts
- Gene therapy for neurodegenerative disorders8 Jul 2025US 12,350,311 B2Genzyme Corporation
- Delivery of large payloads8 Jul 2025US 12,350,368 B2Massachusetts Institute of Technology
- Modified capsid proteins for enhanced intra-articular delivery of adenovirus-associated virus (aav) vectors13 Aug 2026US 2026/0234665 A1The University of North Carolina at Chapel Hill
- Gene therapies for lysosomal disorders23 Jul 2026US 2026/0209718 A1Prevail Therapeutics, Inc.
- Methods for treating cancer with hyperactive adar enzymes19 Mar 2026US 2026/0077026 A1Marine Biological Laboratory
- Viral particles retargeted to skeletal muscle2 Oct 2025US 2025/0304918 A1Regeneron Pharmaceuticals, Inc.
- Gene Therapy For Neurodegenerative Disorders18 Sep 2025US 2025/0288644 A1Genzyme Corporation
Most cited
By later US patents
- CNS targeting AAV vectors and methods of use thereof91US 9,102,949 B2University of Massachusetts · 2015
- CNS targeting AAV vectors and methods of use thereof57US 9,701,984 B2University of Massachusetts · 2017
- Viral vectors with modified transduction profiles and methods of making and using the same41US 9,409,953 B2The University of North Carolina at Chapel Hill · 2016
- Gene therapy for neurodegenerative disorders16US 10,369,193 B2Genzyme Corporation · 2019
- Gene therapy for neurodegenerative disorders12US 9,415,119 B2Genzyme Corporation · 2016